The US FDA granted approval for Medtronic’s Guardian Connect continuous glucose monitor.
The new device is intended for people with diabetes, of ages 14 to 75 years.
Continuous glucose monitoring provides real-time glucose value and trend information about glucose levels for people with diabetes.
In addition, the system predicts future high and low glucose events and provides access to additional algorithms and insights that can inform users of clinically relevant glucose patterns.
This allows for appropriate intervention to mitigate hyperglycemia or hypoglycemia, increasing the patient’s time in the optimal glucose target range.
To use the device, the person with diabetes inserts a tiny sensor beneath the skin in the abdomen or upper arm. The sensor, which measures glucose levels from the interstitial fluid under the skin, is attached to a transmitter that sends readings to an app, wearable monitor or insulin pump every five minutes.